Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy.
Madhawa K De SilvaDavid L H ChanElizabeth J BernardAlice J ConnerSophie L MascallDale L BaileyPaul J RoachStephen J ClarkeConnie I DiakosNick PavlakisGeoff SchembriPublished in: Pancreas (2024)
Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.